Clinical Trial Update: Study to Evaluate Pregnancy Outcomes in Risankizumab Exposed Pregnancies Relative to Those Non-risankizumab Exposed Pregnancies in Women With FDA Approved Indications

View source ↗

Summary

A clinical trial assessing pregnancy outcomes in risankizumab-exposed pregnancies versus non-exposed pregnancies in women with FDA-approved indications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease
• Plaque Psoriasis
• Psoriatic Arthritis

Drugs mentioned

• SKYRIZI (risankizumab-rzaa)

Snippet

Sponsor: AbbVie | Conditions: Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease, or Other Conditions for Which Risankizumab is an FDA-approved Treatment | Status: RECRUITING